These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35790696)

  • 21. Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    World J Gastroenterol; 2021 May; 27(17):2039-2053. PubMed ID: 34007138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.
    Kalra PR; Cleland JGF; Petrie MC; Thomson EA; Kalra PA; Squire IB; Ahmed FZ; Al-Mohammad A; Cowburn PJ; Foley PWX; Graham FJ; Japp AG; Lane RE; Lang NN; Ludman AJ; Macdougall IC; Pellicori P; Ray R; Robertson M; Seed A; Ford I;
    Lancet; 2022 Dec; 400(10369):2199-2209. PubMed ID: 36347265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy of two forms of intravenous iron--saccharated ferric oxide and cideferron--for iron deficiency anemia.
    Araki T; Takaai M; Miyazaki A; Ohshima S; Shibamiya T; Nakamura T; Yamamoto K
    Pharmazie; 2012 Dec; 67(12):1030-2. PubMed ID: 23346769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide.
    Yamamoto S; Okada Y; Mori H; Fukumoto S; Tanaka Y
    Intern Med; 2012; 51(17):2375-8. PubMed ID: 22975552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.
    Zoller H; Wolf M; Blumenstein I; Primas C; Lindgren S; Thomsen LL; Reinisch W; Iqbal T
    Gut; 2023 Apr; 72(4):644-653. PubMed ID: 36343979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial.
    Cleland JGF; Kalra PA; Pellicori P; Graham FJ; Foley PWX; Squire IB; Cowburn PJ; Seed A; Clark AL; Szwejkowski B; Banerjee P; Cooke J; Francis M; Clifford P; Wong A; Petrie C; McMurray JJV; Thomson EA; Wetherall K; Robertson M; Ford I; Kalra PR;
    Eur Heart J; 2024 Apr; 45(16):1410-1426. PubMed ID: 38446126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correction to: Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study.
    Kawabata H; Tamura T; Tamai S; Fujibayashi A; Sugimura M;
    Int J Hematol; 2022 Dec; 116(6):976-977. PubMed ID: 36346569
    [No Abstract]   [Full Text] [Related]  

  • 28. The Impact of Ferric Derisomaltose on Cardiovascular and Noncardiovascular Events in Patients With Anemia, Iron Deficiency, and Heart Failure With Reduced Ejection Fraction.
    Ray R; Ford I; Cleland JGF; Graham F; Ahmed FZ; Al-Mohammad A; Cowburn PJ; Critoph C; Kalra PA; Lane RE; Ludman A; Pellicori P; Petrie MC; Robertson M; Seed A; Squire I; Kalra PR; ; ; ;
    J Card Fail; 2024 May; 30(5):682-690. PubMed ID: 37926238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose.
    Kennedy NA; Achebe MM; Biggar P; Pöhlmann J; Pollock RF
    Int J Clin Pharm; 2023 Jun; 45(3):604-612. PubMed ID: 37010731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular safety.
    Blumenstein I; Shanbhag S; Langguth P; Kalra PA; Zoller H; Lim W
    Expert Opin Drug Saf; 2021 Jul; 20(7):757-769. PubMed ID: 33993818
    [No Abstract]   [Full Text] [Related]  

  • 31. Letter to the editor: in response to: Richard F Pollock & Patrick Biggar. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia.
    Aksan A; Dignass A; Stein J
    Expert Rev Hematol; 2022 Apr; 15(4):383-384. PubMed ID: 33511892
    [No Abstract]   [Full Text] [Related]  

  • 32. A case of hypophosphatemia and elevated intact fibroblast growth factor 23 levels after short-term saccharated ferric oxide administration in a young woman and database analysis of adverse drug reactions in Japan.
    Kinoshita T; Kondo Y; Sakazaki Y; Imaizumi H; Takimoto N; Ishitsuka Y
    Bone Rep; 2024 Jun; 21():101754. PubMed ID: 38584682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review.
    Bazeley JW; Wish JB
    Am J Kidney Dis; 2022 Jun; 79(6):868-876. PubMed ID: 34758368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized trial of intravenous iron-induced hypophosphatemia.
    Wolf M; Chertow GM; Macdougall IC; Kaper R; Krop J; Strauss W
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension.
    Pergola PE; Kopyt NP
    Am J Kidney Dis; 2021 Dec; 78(6):846-856.e1. PubMed ID: 34029682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous ferric derisomaltose for the treatment of iron deficiency anemia.
    Auerbach M; Henry D; DeLoughery TG
    Am J Hematol; 2021 Jun; 96(6):727-734. PubMed ID: 33580972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world experience of intravenous ferric derisomaltose evaluated through safety and efficacy reporting in the UK.
    Sinclair RCF; Nadaraja S; Kennedy NA; Wakatsuki M; Bhandari S
    Sci Rep; 2022 Nov; 12(1):18859. PubMed ID: 36344720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Evaluation of the efficacy of intravenous iron III-hydroxide saccharate for treating adult patients with iron deficiency anemia].
    Cançado RD; Brasil SA; Noronha TG; Chiattone CS
    Rev Assoc Med Bras (1992); 2005; 51(6):323-8. PubMed ID: 16444338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
    Ziedan A; Bhandari S
    Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.